Grifols (NASDAQ:GRFS) Shares Gap Up - What's Next?

Grifols, S.A. (NASDAQ:GRFS - Get Free Report) shares gapped up prior to trading on Monday . The stock had previously closed at $7.33, but opened at $7.62. Grifols shares last traded at $7.63, with a volume of 237,353 shares changing hands.

Analyst Ratings Changes

Separately, Berenberg Bank upgraded Grifols to a "strong-buy" rating in a research report on Tuesday, October 29th.

Grifols Price Performance

The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26. The company has a 50-day moving average of $8.43 and a 200 day moving average of $8.10.

Hedge Funds Weigh In On Grifols

Hedge funds and other institutional investors have recently modified their holdings of the company. GAMMA Investing LLC increased its stake in Grifols by 49.4% in the 3rd quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company's stock worth $30,000 after buying an additional 1,135 shares in the last quarter. Signaturefd LLC grew its position in shares of Grifols by 66.2% during the third quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company's stock valued at $48,000 after purchasing an additional 2,153 shares in the last quarter. HighTower Advisors LLC grew its position in shares of Grifols by 12.5% during the third quarter. HighTower Advisors LLC now owns 13,930 shares of the biotechnology company's stock valued at $123,000 after purchasing an additional 1,546 shares in the last quarter. AQR Capital Management LLC purchased a new position in shares of Grifols during the second quarter valued at about $89,000. Finally, Chesapeake Capital Corp IL purchased a new position in shares of Grifols during the third quarter valued at about $148,000.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.